B2Broker Introduces Latest Technology Components of B2Trader Matching Engine as a Software Solution
B2Broker, a liquidity and technology provider of solutions for the crypto and Forex industry, has added a new range of features to its matching engine, B2Trader, enabling client demands to be met in record time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005197/en/
Image 1: Screenshot showing users. (Photo: Business Wire)
About B2Trader
B2Trader is used by many of the world's best-known exchanges, MTF Brokers, Security Exchanges, Market Makers, Spot FX Brokers and EMIs, with the job of matching an incoming market order of the user with the existing limit order of another user. The engine works 24/7 in parallel with the round-the-clock rhythm of the crypto markets without any breaks.
Matching - Tech Stack, Details, Scheme of the Module and Capacity
The order matcher is designed for crypto trading and low-latency automatic trading systems and is able to fulfill 10,000 requests per second with an average latency of 500 ms. The new matching engine uses C # ASP.NET Core programming languages for the back-end and includes a trading mechanism for matching orders, various APIs and synchronization services and databases.
API - All Details, Languages and Capacity
The stability and performance aspects of the engine now allow for the development of faster APIs. B2Broker has introduced a new API for robotic trading and public data access which handles trading and public requests much faster while positively affecting the overall system performance (trading and public API - Websocket/Rest). With new API access, users can connect directly into the matching system and operate ultra-fast trading orders or receive crypto markets data on DOMs.
Security
B2Trader incorporates a series of the latest features to provide the best possible protection from technical and fraud threats. These include an anti-throttling system, anti-spoofing protection and DDoS protection. Other security features include 2FA, adding an extra layer of security, and an IP Whitelist which puts in place a restriction to work only under a certain IP inside the admin panel.
Front End
A professional GUI meets all requirements from beginners to pro-traders. It provides a multitude of features and a high degree of customisation including adaptive colouring, easy and highly responsive navigation menu, grouping for sorting options into a more convenient structure and a customisable Dynamic User Interface with colour and font customisation which includes easy addition of widgets, workspaces for various trading styles, widgets customization and workspace arrangement.
Some recent developments include a watchlist that allows for the addition of favourite instruments to monitor percentage changes, White/Night mode, a broad variety of deposit/withdrawal methods featuring B2BinPay, IOC/FOK order settings and the availability of multiple sources of liquidity available for connection with B2Trader.
Back Office
B2Trader admin takes care of all operational options that need to be carried out by the exchange daily, delivering them in a user-friendly and sophisticated manner. The admin module allows you to manage and set up and change exchange user trading/withdrawal permissions, extract information on the history of user logins to the exchange UI, transfer history, user asset balances, information on a user's aggregate balance in indicative currency, setup commissions for the markets or particular user and more, with safety always a top priority.
SAAS AWS
B2Trader uses hosting solutions that dynamically scale resources and support the most demanding and highly loaded projects. AWS hosting offers high levels of availability, scalability and performance, requiring higher amounts of management and administration that is fully organised by B2Broker.
Third-Party Integrations
To set up and run a successful exchange business, there needs to be an equal focus on sales and marketing, compliance, deposits, withdrawals, licenses, and the regulatory framework, etc. To this end, B2Broker has integrated a variety of services that help exchanges manage all aspects effectively. These include B2BinPay, B2Core, Crystal Blockchain, Leading Fiat PSPs, SumSub, B2BX and MarksMan.
The latest features combined with external integrations further enhance B2Trader to deliver a matching engine with the ultimate in performance and functionality, while ensuring that all market participants are given the best execution.
New clients can now benefit from a discount on setup, offering more favourable pricing than 2020 due to COVID and the new market bull run.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005197/en/
Contact information
Rosemary Barnes
Head of PR
pr@b2broker.net
www.b2broker.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 10:00:00 EET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 09:00:00 EET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 08:30:00 EET | Press release
4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo ® in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 08:30:00 EET | Press release
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.” Cardiovascular disease i
Azafaros to Present at J.P. Morgan’s 44 th Annual Healthcare Conference8.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom